Merck/Schering-Plough Announces Update for the IMPROVE-IT Trial
15th Nov 2005, 17:25 GMT
Merck/Schering-Plough Pharmaceuticals announced the commencement of patient enrollment in its large-scale, clinical outcomes trial conducted for VYTORIN.
Merck/Schering-Plough Announces Update for the IMPROVE-IT Trial related news:
- Schering-Plough Licenses Technology — StratWire - Business of Healthcare NewsFeed
- Schering-Plough Posts Golimumab Data — Operations-Related News from StratCenter.com
- Positive phase I trial for Schering-Plough HCV treatment — Pharmaceutical Business Review Online
- Pfizer's Lipitor Data Favors Schering-Plough, Merck — Forbes.com Market News
- Schering-Plough and Oncomethylome collaborate against brain cancer — Pharmaceutical Business Review Online
- Schering-Plough to Webcast Presentation at Credit Suisse 1st Boston Annual Health Care Conference — Operations-Related News from StratCenter.com
- Centocor and Schering-Plough drug shows promise in RA — Pharmaceutical Business Review Online
- Centocor & Schering-Plough next generation biologic promising in phase 2 rheumatoid arthritis trial — EurekAlert! - Technology, Engineering and Computer Science
- Centocor: Centocor and Schering-Plough Next-Generation Biologic Shows Promise in the Treatment of Rheumatoid Arthritis in Phase 2 Trial — Market Wire - Pharmaceuticals and Biotech
- Schering-Plough to Webcast Presentation at Credit Suisse First Boston Annual Health Care Conference — PR Newswire: All Releases
Latest news from Pharmaceuticals News from StratCenter.com:
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection
- Medco to Present at the Credit Suisse Annual Healthcare Conference
- Bob Dole Medicare Podcast Helps Seniors through 2007 Drug Coverage Enrollment Process
- Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!
- Care Clinic Purchases Pinnacle Easy Care
- Pegasystems Enhances 2 Business Critical BPM Frameworks for the Healthcare Industry
- Isis Cholesterol Drug Shown Effective
- Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
- Nymox Reports Q3 2006 Financial Results
- RemoteMDx Raises $6 mln in Private Placement